metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	nivolumab plus SoC
	CheckMate 649 (PDL1 CPS>5), 2021 Lancet 2021 Jun 4;S0140-6736(21)00797-2. NCT02872116	RCT	mGC or mGEJC - L1 - HER2 neg/PDL1 positive	nivolumab plus chemotherapy	ICC (XELOX, FOLFOX)	previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma, only patients with PDL1 CPS>5	473 / 482	some concern	conclusif	demonstrated 29 % decrease in deaths (OS) (PE) demonstrated 32 % decrease in progression or deaths (PFS) (PE)
	CheckMate 649 (PDL1 CPS>1), 2021 Lancet 2021 Jun 4;S0140-6736(21)00797-2. NCT02872116	RCT	mGC or mGEJC - L1 - HER2 neg/PDL1 positive	nivolumab plus chemotherapy	ICC (XELOX, FOLFOX)	previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma, only patients with PDL1 CPS>1	641 / 655	some concern	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) suggested 26 % decrease in progression or deaths (PFS)